SecurityTYO:8316 / Sumitomo Mitsui Financial Group,inc.
Institutional Owners153 (153 N-Q Owners)

Institutional Stock Ownership and Shareholders

Sumitomo Mitsui Financial Group,inc. (TYO:8316) has 153 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .

Sumitomo Mitsui Financial Group,inc. (TYO:8316) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-10-27 N-Q Valic Co I (see advisory)
2018-01-26 N-Q Jpmorgan Institutional Trust (see advisory)
2017-12-28 N-Q Target Portfolio Trust (see advisory)
2017-11-27 N-Q Voya Partners Inc (see advisory)
2018-01-26 N-Q Vanguard Scottsdale Funds (see advisory)
2017-11-22 N-Q Ssga Active Trust (see advisory)
2017-09-27 N-Q Lord Abbett Securities Trust (see advisory)
2017-11-20 N-Q Dreyfus Variable Investment Fund (see advisory)
2018-01-26 N-Q Fidelity Advisor Series Ii (see advisory)
2018-02-28 N-Q Goldman Sachs Trust (see advisory)
2017-12-29 N-Q Nushares Etf Trust (see advisory)
2018-01-29 N-Q American Beacon Funds (see advisory)
2017-09-28 N-Q Vanguard Star Funds (see advisory)
2018-03-01 N-Q Spdr Index Shares Funds (formerly Streettracks Index Shares Funds) (see advisory)
2017-10-30 N-Q John Hancock Bond Trust (see advisory)
2018-02-27 N-Q Putnam Asset Allocation Funds (see advisory)
2017-11-28 N-Q Pacific Select Fund (see advisory)
2018-01-25 N-Q Putnam Funds Trust (see advisory)
2017-09-29 N-Q Global Macro Absolute Return Advantage Portfolio (see advisory)
2017-11-27 N-Q Voya Balanced Portfolio Inc (see advisory)
2018-02-26 N-Q Blackrock Funds Ii (see advisory)
2017-09-26 N-Q Voya Mutual Funds (see advisory)
2018-03-01 N-Q First Investors Equity Funds (see advisory)
2017-11-22 N-Q Blackrock Index Funds, Inc. (see advisory)
2018-02-27 N-Q Doubleline Funds Trust (see advisory)
2017-12-29 N-Q Adviser Managed Trust (see advisory)
2017-11-28 N-Q Putnam International Equity Fund /ma/ (see advisory)
2018-01-26 N-Q Voya Global Equity Dividend & Premium Opportunity Fund (see advisory)
2018-02-26 N-Q Blackrock Funds (see advisory)
2018-02-27 N-Q Bernstein Sanford C Fund Inc (see advisory)
2017-09-27 N-Q Managed Account Series (see advisory)
2018-03-01 N-Q Causeway Capital Management Trust (see advisory)
2017-11-22 N-Q Quantitative Master Series Llc (see advisory)
2018-01-26 N-Q Brinker Capital Destinations Trust (see advisory)
2017-11-17 N-Q Lazard Retirement Series Inc (see advisory)
2017-11-29 N-Q Ubs Relationship Funds (see advisory)
2018-01-23 N-Q Schwab Strategic Trust (see advisory)
2018-01-26 N-Q Sei Catholic Values Trust (see advisory)
2017-10-27 N-Q Ab Global Risk Allocation Fund, Inc. (see advisory)
2017-11-28 N-Q Pimco Equity Series (see advisory)
2017-09-27 N-Q Advisors' Inner Circle Fund (see advisory)
2018-02-28 N-Q Seasons Series Trust (see advisory)
2017-12-28 N-Q Fidelity Puritan Trust (see advisory)
2017-09-29 N-Q Tax-managed International Equity Portfolio (see advisory)
2018-03-01 N-Q Aqr Funds (see advisory)
2017-09-29 N-Q Ishares U.s. Etf Trust (see advisory)
2017-09-28 N-Q VANGUARD WINDSOR FUNDS (see advisory)
2018-01-25 N-Q Dbx Etf Trust (see advisory)
2017-09-27 N-Q 1290 Funds (see advisory)
2017-12-20 N-Q Mfs Series Trust Vii (see advisory)
2017-11-28 N-Q Ab Cap Fund, Inc. (see advisory)
2017-11-27 N-Q Voya Intermediate Bond Portfolio (see advisory)
2018-02-28 N-Q Guggenheim Strategy Funds Trust (see advisory)
2018-02-28 N-Q VANGUARD HORIZON FUNDS (see advisory)
2017-09-28 N-Q Vanguard International Equity Index Funds (see advisory)
2017-11-22 N-Q Thrivent Mutual Funds (see advisory)
2018-03-01 N-Q Pimco Funds (see advisory)
2017-11-24 N-Q Transamerica Series Trust (see advisory)
2018-02-28 N-Q Gps Funds I (see advisory)
2017-11-30 N-Q Johnson Mutual Funds Trust (see advisory)
2017-09-26 N-Q Wilmington Funds (see advisory)
2018-02-28 N-Q Prudential Investment Portfolios, Inc. (see advisory)
2018-03-01 N-Q Alps Series Trust (see advisory)
2018-02-26 N-Q Allianz Funds Multi-strategy Trust (see advisory)
2017-11-29 N-Q Prudential Short-term Corporate Bond Fund, Inc. (see advisory)
2017-11-22 N-Q State Street Institutional Investment Trust (see advisory)
2017-09-29 N-Q American Beacon Institutional Funds Trust (see advisory)
2017-11-29 N-Q Vanguard Bond Index Funds (see advisory)
2018-03-01 N-Q Sei Institutional International Trust (see advisory)
2018-03-01 N-Q Calvert Responsible Index Series, Inc. (see advisory)
2018-03-01 N-Q City National Rochdale Funds (see advisory)
2017-09-27 N-Q Blackrock Global Allocation Fund, Inc. (see advisory)
2017-11-29 N-Q Ubs Funds (see advisory)
2017-11-29 N-Q Allianz Variable Insurance Products Fund Of Funds Trust (see advisory)
2017-11-29 N-Q Allianz Variable Insurance Products Trust (see advisory)
2017-09-20 N-Q Dreyfus/laurel Funds Inc (see advisory)
2017-10-30 N-Q Claymore Exchange-traded Fund Trust 2 (see advisory)
2018-01-26 N-Q Jpmorgan Trust I (see advisory)
2018-01-26 N-Q Fidelity Rutland Square Trust Ii (see advisory)
2017-11-29 N-Q Investment Managers Series Trust (see advisory)
2017-11-28 N-Q Matthews International Funds (see advisory)
2017-11-29 N-Q Tiff Investment Program (see advisory)
2017-11-28 N-Q Jpmorgan Insurance Trust (see advisory)
2017-11-27 N-Q Lazard Funds Inc (see advisory)
2017-09-29 N-Q Global Macro Portfolio (see advisory)
2017-11-29 N-Q Janus Investment Fund (see advisory)
2018-02-26 N-Q Ab Global Bond Fund, Inc. (see advisory)
2017-11-29 N-Q Deutsche Variable Series Ii (see advisory)
2017-11-29 N-Q Sma Relationship Trust (see advisory)
2017-09-20 N-Q Dreyfus Index Funds Inc (see advisory)
2017-12-21 N-Q American Pension Investors Trust (see advisory)
2017-09-25 N-Q Wells Fargo Funds Trust (see advisory)
2018-02-28 N-Q Wisdomtree Trust (see advisory)
2017-11-28 N-Q Northern Lights Fund Trust (see advisory)
2017-11-22 N-Q Principal Variable Contracts Funds Inc (see advisory)
2018-01-25 N-Q Columbia Funds Series Trust Ii (see advisory)
2017-11-27 N-Q John Hancock Hedged Equity & Income Fund (see advisory)
2018-03-15 N-Q Madison Funds (see advisory)
2017-11-22 N-Q Ssga Master Trust (see advisory)
2017-11-14 N-Q Russell Investment Funds (see advisory)
2018-02-28 N-Q Ishares Trust (see advisory)
2017-09-28 N-Q Mfs Series Trust Xv (see advisory)
2017-11-20 N-Q Ohio National Fund Inc (see advisory)
2017-09-29 N-Q Putnam Income Fund (see advisory)
2018-02-28 N-Q Morgan Stanley Institutional Fund Trust (see advisory)
2018-01-26 N-Q Fidelity Salem Street Trust (see advisory)
2018-01-23 N-Q Mfs Series Trust Iv (see advisory)
2018-02-26 N-Q TIAA-CREF FUNDS (see advisory)
2017-12-28 N-Q Eaton Vance Growth Trust (see advisory)
2017-11-28 N-Q Pimco Etf Trust (see advisory)
2017-11-28 N-Q Legg Mason Partners Variable Income Trust (see advisory)
2017-11-27 N-Q Brighthouse Funds Trust I (see advisory)
2017-09-28 N-Q Mfs Series Trust Vi (see advisory)
2017-09-27 N-Q Advisors' Inner Circle Fund Iii (see advisory)
2017-11-17 N-Q Lazard World Dividend & Income Fund, Inc. (see advisory)
2017-12-28 N-Q George Putnam Balanced Fund (see advisory)
2018-01-24 N-Q PRINCIPAL FUNDS INC (see advisory)
2017-09-29 N-Q Eaton Vance Special Investment Trust (see advisory)
2018-03-01 N-Q Rivernorth Funds (see advisory)
2017-11-29 N-Q Deutsche Institutional Funds (see advisory)
2017-11-29 N-Q Boston Trust & Walden Funds (see advisory)
2017-12-29 N-Q Sunamerica Series Trust (see advisory)
2018-03-01 N-Q Loomis Sayles Funds I (see advisory)
2018-02-28 N-Q Franklin Templeton Etf Trust (see advisory)
2018-03-14 N-Q Steward Funds, Inc. (see advisory)
2017-09-26 N-Q Deutsche Market Trust (see advisory)
2017-11-27 N-Q Voya Variable Insurance Trust (see advisory)
2017-09-28 N-Q Jpmorgan Trust Ii (see advisory)
2018-02-28 N-Q Guggenheim Funds Trust (see advisory)
2018-02-20 N-Q Dreyfus Stock Funds (see advisory)
2017-11-22 N-Q Blackrock Enhanced International Dividend Trust (see advisory)
2017-11-28 N-Q Putnam Variable Trust (see advisory)
2017-11-22 N-Q COLLEGE RETIREMENT EQUITIES FUND (see advisory)
2017-09-28 N-Q Vanguard Trustees' Equity Fund (see advisory)
2018-02-28 N-Q Marsico Investment Fund (see advisory)
2018-02-28 N-Q Vanguard Malvern Funds (see advisory)
2017-09-29 N-Q Goldman Sachs Trust Ii (see advisory)
2018-02-26 N-Q Legg Mason Global Asset Management Trust (see advisory)
2018-01-26 N-Q Fidelity Commonwealth Trust Ii (see advisory)
2017-11-28 N-Q Pimco Equity Series Vit (see advisory)
2018-02-27 N-Q Massmutual Premier Funds (see advisory)
2018-02-27 N-Q Northern Funds (see advisory)
2018-02-27 N-Q Blackstone Alternative Investment Funds (see advisory)
2018-01-23 N-Q Schwab Investments (see advisory)
2018-01-26 N-Q VANGUARD WORLD FUND (see advisory)
2017-09-26 N-Q Legg Mason Etf Investment Trust (see advisory)
2017-09-27 N-Q Advisors' Inner Circle Fund Ii (see advisory)
2018-02-28 N-Q Pacific Funds Series Trust (see advisory)
2017-09-25 N-Q Eagle Series Trust (see advisory)
2018-02-28 N-Q Ivy Funds (see advisory)
2018-03-01 N-Q Sei Institutional Managed Trust (see advisory)
2018-02-27 N-Q Massmutual Select Funds (see advisory)
2017-11-28 N-Q Western Asset Funds Inc (see advisory)

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.


  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( TYO:8316 / Sumitomo Mitsui Financial Group,inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...